APA (7th ed.) Citation

Costes-Tertrais, D., Hueso, T., Gastinne, T., Thieblemont, C., Oberic, L., Bouabdallah, K., . . . Le Gouill, S. (2022). Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation, 57(4), 627. https://doi.org/10.1038/s41409-022-01596-8

Chicago Style (17th ed.) Citation

Costes-Tertrais, Domitille, et al. "Bendamustine-EAM Versus R-BEAM After High-dose Cytarabine-based Induction in Newly Diagnosed Patients with Mantle Cell Lymphoma, a LYSA Retrospective Study." Bone Marrow Transplantation: Official Journal of the European Society for Blood and Marrow Transplantation 57, no. 4 (2022): 627. https://doi.org/10.1038/s41409-022-01596-8.

MLA (9th ed.) Citation

Costes-Tertrais, Domitille, et al. "Bendamustine-EAM Versus R-BEAM After High-dose Cytarabine-based Induction in Newly Diagnosed Patients with Mantle Cell Lymphoma, a LYSA Retrospective Study." Bone Marrow Transplantation: Official Journal of the European Society for Blood and Marrow Transplantation, vol. 57, no. 4, 2022, p. 627, https://doi.org/10.1038/s41409-022-01596-8.